MX2023001493A - Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma. - Google Patents

Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma.

Info

Publication number
MX2023001493A
MX2023001493A MX2023001493A MX2023001493A MX2023001493A MX 2023001493 A MX2023001493 A MX 2023001493A MX 2023001493 A MX2023001493 A MX 2023001493A MX 2023001493 A MX2023001493 A MX 2023001493A MX 2023001493 A MX2023001493 A MX 2023001493A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
preparation
aquaporin inhibitor
pharmaceutically acceptable
aquaporin
Prior art date
Application number
MX2023001493A
Other languages
English (en)
Inventor
Yong Qian
Ruiwen Shi
Amy Liu
Yanhong Liu
Aijuan Feng
Jinsheng Ren
Tian Song
Original Assignee
Jiangsu Simcere Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharm Co Ltd filed Critical Jiangsu Simcere Pharm Co Ltd
Publication of MX2023001493A publication Critical patent/MX2023001493A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporciona una composición farmacéutica de un inhibidor de la acuaporina y a un método para la preparación del mismo. La composición farmacéutica comprende fosfato de 2-((3, 5-bis(trifluorometil) fenil)carbamoil)-4-clorofenilo dihidrogenado o una sal farmacéuticamente aceptable del mismo, o un solvato farmacéuticamente aceptable del mismo, y meglumina. La composición farmacéutica del inhibidor de la acuaporina y el método de preparación del mismo tienen las siguientes ventajas: el proceso es simple, tiene una fuerte operabilidad y es propicio para la producción industrial, y el producto tiene una buena estabilidad y, obviamente, menos contenido de impurezas degradables, lo que garantiza la eficacia del medicamento.
MX2023001493A 2020-08-05 2021-08-04 Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma. MX2023001493A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010779964 2020-08-05
PCT/CN2021/110506 WO2022028459A1 (en) 2020-08-05 2021-08-04 Pharmaceutical composition of aquaporin inhibitor and preparation method thereof

Publications (1)

Publication Number Publication Date
MX2023001493A true MX2023001493A (es) 2023-06-23

Family

ID=80120008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001493A MX2023001493A (es) 2020-08-05 2021-08-04 Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma.

Country Status (12)

Country Link
US (1) US20230293556A1 (es)
EP (1) EP4192442A1 (es)
JP (1) JP2023536509A (es)
KR (1) KR20230137284A (es)
CN (1) CN117337182A (es)
AU (1) AU2021323181A1 (es)
BR (1) BR112023002129A2 (es)
CA (1) CA3187716A1 (es)
IL (1) IL300341A (es)
MX (1) MX2023001493A (es)
TW (1) TW202228714A (es)
WO (1) WO2022028459A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103656A1 (ja) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 Ｏ−置換ヒドロキシアリール誘導体
US9316633B2 (en) * 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
JP6238969B2 (ja) * 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法
RU2691951C2 (ru) * 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы
LT3080134T (lt) * 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
US11117909B2 (en) * 2016-05-13 2021-09-14 Aeromics, Inc. Crystals

Also Published As

Publication number Publication date
CA3187716A1 (en) 2022-02-10
WO2022028459A1 (en) 2022-02-10
EP4192442A1 (en) 2023-06-14
AU2021323181A1 (en) 2023-03-23
KR20230137284A (ko) 2023-10-04
JP2023536509A (ja) 2023-08-25
TW202228714A (zh) 2022-08-01
US20230293556A1 (en) 2023-09-21
BR112023002129A2 (pt) 2023-04-18
IL300341A (en) 2023-04-01
CN117337182A (zh) 2024-01-02

Similar Documents

Publication Publication Date Title
CA2443952C (en) Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
EP0189788B1 (de) Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
US20120149706A1 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
WO2003063864A3 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
EP1041982A1 (en) INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
US8624063B2 (en) Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing
CA2414967A1 (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
DE69624136T2 (de) Verwendung von ritonavir (abt-538) zur verbesserung der pharmakokinetik von arzneimitteln, die durch cytochrom p450 metabolisiert werden, im rahmen einer behandlung von aids
WO2000041698A1 (en) φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
MX2023001493A (es) Composicion farmaceutica de un inhibidor de la acuaporina y metodo para la preparacion de la misma.
MX2022012896A (es) Pirrolo[1,2-d][1,2,4]triazin-2-ilacetamidas como inhibidores de la ruta del inflamasoma nlrp3.
MX2022013323A (es) Compuestos triciclicos como inhibidores de nlrp3.
HUP0302068A2 (hu) COX-2 inhibitorok alkalmazása immundeficienciával járó rendellenességek kezelésére vagy megelőzésére és ezeket tartalmazó gyógyszerkészítmények
GEP20053492B (en) 5-Chloro-3-(4-Methanesulfonylphenyl)-6'-Methyl- [2,3']Bipyridinyl in Pure Crystalline Form and Process for Production Thereof
EP3220919A1 (en) Antibacterial compounds
MX2023002371A (es) Derivado de nitrilo que actua como inhibidor de la dipeptidil peptidasa 1 y uso del mismo.
MX2023006854A (es) Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma.
BR0315820A (pt) Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização
ZA202206481B (en) Amide derivative and preparation method therefore and use thereof in medicine
MX2023000625A (es) Nuevos compuestos como inhibidor de histona desacetilasa 6, y composicion farmaceutica que los comprende.
DE10017480A1 (de) Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
AU639785B2 (en) Use of substituted beta-hydroxyethylamines as potent inhibitors of the exoenzymes of fungi
ATE184793T1 (de) Die verwendung von carbostyrilderivaten zur herstellung eines arzneimittels zur hemmung der produktion von interleukin-8
MX2020004588A (es) Inhibidor de proteasa de doble cabeza.
TW429146B (en) Pharmaceutical composition for prophylaxis and treatment of type I allergic diseases